GREAT NECK, N.Y., Feb. 23, 2011 /CNW/ -- Scarguard Labs, LLC, a closely held company specializing in the treatment of scars, psoriasis and other dermatological problems through the use of multi-technology drugs enhanced by a proprietary contact delivery system, announced today that they have received approval from Health Canada to sell Scarguard to physicians and consumers throughout Canada.
"We are very pleased to gain approval for retail in our first international market," stated Dr. Joel Studin, Chairman and CEO of Scarguard Labs. "The Canadian market provides an opportunity for Scarguard to increase overall sales and profits by an estimated 15% while driving brand awareness with physicians as well as consumers."
About Scarguard Labs, LLC.
Scarguard Labs, LLC is a closely held pharmaceutical company specializing in dermatological medications employing an internationally patented delivery system designed to enhance drug effectiveness utilizing a multi-technology approach. Our flagship product, Scarguard, is the most frequently dispensed in plastic surgery offices product for scars since 2001. In addition, it can be found in most pharmacies, drug distributors, mass merchants, and major grocery chains throughout the United States. We have multiple topical prescription and non-prescription drugs for eczema, psoriasis, and many other dermatological conditions in the marketplace, or in varying stages of development. For more information, please visit our website at www.scarguard.com
Richard E. Pino
Chief Financial Officer / Investor Relations
Scarguard Labs, LLC
SOURCE Scarguard Labs, LLC
For further information: Richard E. Pino, Chief Financial Officer Investor Relations, Scarguard Labs, LLC, +1-516-482-8050, firstname.lastname@example.org